Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topiramate for weight reduction and metabolic syndrome in obese inpatients with schizophrenia or schizoaffective disorder
IRCT20210622051665N1Phase 3Completed
- Sponsor
- University of Social Welfare and Rehabilitation Sciences
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in schizophrenia and schizoaffective disorder comparing Topiramate plus background antipsychotic with Placebo plus background antipsychotic (2 arms). Primary endpoints: Weight change, Body mass index change and 6 more. Started Feb 2020; status: completed.
02
Drugs
topiramate
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on IRCT20210622051665N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210622051665N1.